Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311032 · ClinicalTrials.gov registry record
Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas
A clinical trial of Surgery Risk Assessment, sponsored by NYU Langone Health.
- Completed
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT06311032 is a study of Surgery Risk Assessment that has completed, run by NYU Langone Health. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06311032, a study of Surgery Risk Assessment, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.
Conditions Studied
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2023-07-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06311032
The ClinicalTrials.gov registry entry for NCT06311032 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Surgery Risk Assessment appearing as the primary indexed condition, and to 0 interventions.
NCT06311032 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06311032 about?
NCT06311032 is a clinical study titled "Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas". The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.
What is the current status of trial NCT06311032?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2023-03-29. Estimated completion is 2023-07-28.
What conditions does trial NCT06311032 study?
This clinical trial studies the following conditions: Surgery Risk Assessment.
Who is sponsoring clinical trial NCT06311032?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311032 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.